Study Title
A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma (NCT01950364)
Trial Description
This is an open-label trial to estimate the concentrations of MMAE in relapsed/refractory Hodgkin Lymphoma (HL) or relapsed/refractory Systemic Anaplastic Large Cell Lymphoma (sALCL) patients treated with either brentuximab vedotin or brentuximab vedotin + rifampicin.
This trial is sponsored by Millennium Pharmaceuticals. [1]
Study Data
- Conditions:
- Hodgkin Lymphoma (HL)
- Anaplastic Large-cell Lymphoma (sALCL)
- Interventions:
- Drugs used in this trial
- Brentuximab vedotin (Adcetris®; Seattle Genetics, Inc.)
- Rifampicin (Rifadin®; Sanofi-Aventis U.S. LLC)
- Drugs used in this trial
- Phase: I
- Estimated Enrollment: 20
- Start: November 2013
- Estimated Completion: August 2015
- Last verified: February 2015
Study Schematic
Click here to Return to Drug map
Last Editorial review: July 15, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.
